MEISTER PAUL M 4

What Happened
Paul M. Meister, a director of Amneal Pharmaceuticals (AMRX), had restricted stock units (RSUs) convert/vest in early May 2026. The filing shows a gross conversion of 48,747 RSUs into shares (listed as an exercise/conversion), with 30,837 shares ultimately delivered to him (recorded as an award/acquisition at $0.00) and an implied 17,910 shares surrendered or withheld (48,747 gross less 30,837 net). The reported prices for the award and the withheld/disposed shares are $0.00 (typical for RSU settlements); no cash sale on the open market is reported.

Key Details

• Transaction dates: May 6–7, 2026 (Form 4 filed May 8, 2026). Filing appears timely.
• Reported entries: conversion/exercise of 48,747 RSUs (derivative), disposition of 48,747 shares at $0.00, and acquisition of 30,837 shares at $0.00.
• Implied withholding: 17,910 shares (48,747 gross − 30,837 net) appear to have been surrendered/withheld to cover taxes or other obligations.
• Footnotes: F1 confirms each RSU equals a contingent right to one share; F2 notes the RSUs were granted May 6, 2025 and vested May 7, 2026; F3 describes the vesting conditions.
• Shares owned after the transaction are not disclosed in the provided summary of the filing.

Context
RSU vesting and share withholding for taxes are routine corporate actions and do not represent an open-market buy or sell by the insider. The derivative code (M) here reflects conversion/exercise of RSUs into shares; the $0.00 entries indicate grant/settlement and withholding rather than a market transaction.